Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Igm Biosciences Inc. is navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners but are concentrated within 1 distinct art unit. YAO, LEI serves as the busiest examiner, responsible for 1 busiest examiner pending action.
The focus on 1 distinct art unit suggests that the portfolio's current activity is technically specialized within a specific biotechnology niche. While there are 2 distinct examiners involved, the shared art unit means they likely follow similar internal guidelines. This provides the company with two different perspectives on how to satisfy the requirements of this single art unit.
Because the busiest examiner pending count is 1, the workload is evenly split between YAO, LEI and the other examiner. Practitioners should look for consistency in the rejections across the 2 pending office actions, as the 1 distinct art unit often applies a unified technical standard. Success requires addressing the specific concerns of YAO, LEI while leveraging any favorable outcomes from the other examiner to support the overall prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YAO, LEI | 1 | 59.7% | +65.3% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17635490 | MULTIMERIC BISPECIFIC ANTI-CD123 BINDING MOLECULES AND USES THEREOF | LEE, YIE CHIA | 14d |
| 18052388 | MODIFIED J-CHAIN | YAO, LEI | 34d |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18052388 | MODIFIED J-CHAIN | YAO, LEI | 1642 | Other | Final Rejection | 34d | Pending | Nov 03, 2022 |
| 17635490 | MULTIMERIC BISPECIFIC ANTI-CD123 BINDING MOLECULES AND USES THEREOF | LEE, YIE CHIA | 1642 | §103Other | Non-Final OA | 14d | Pending | Feb 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial